

Publicly Funded Pneumococcal Conjugate 21 Vaccine for Select Individuals 65 Years and Older

Information Bulletin No. 1
Published by Population Health Branch
November 2025

Effective December 1, 2025:

1. Merck's [CAPVAXIVE®](#) pneumococcal conjugate 21-valent vaccine (Pneu-C-21) will be provincially funded for select individuals age 65 years and older who meet eligibility criteria below.
2. Pfizer's PREVNAR 20® (Pneu-C-20) vaccine will no longer be provincially funded for most individuals 65 years and older.

Pneu-C-21 vaccine eligibility for adults 65 years and older

1. Individuals who do not have documentation of receiving previous pneumococcal vaccines are eligible to receive one dose of Pneu-C-21.
2. Individuals who have at least one qualifying risk factor below **may be** eligible for immunization based on their previous pneumococcal immunization history.
 - LTC, PHC or group home facility resident
 - Acquired complement deficiency
 - Asplenia
 - Cancer (excluded if in remission)
 - Congenital immunodeficiency
 - HIV
 - Kidney disease
 - Sickle cell disease or other hemoglobinopathies
 - Immunosuppression related to disease or medical treatment
 - Hematopoietic stem cell transplant recipients

Additional information

- A Pneu-C-21 vaccine [fact sheet](#) will be posted soon and must be provided to individuals to obtain their informed consent for immunization.
- Updated Pneu-C-20 and new Pneu-C-21 vaccine information will be added November 28, 2025 to the [Saskatchewan Immunization Manual Chapter 10](#), including an immunization recommendation table for each vaccine:
 - *Pneu-C-20 Immunization Schedules for Individuals Who Have Qualifying Medical/ Lifestyle Risk Factors.*
 - *Pneu-C-21 Immunization Schedules for Individuals 65 Years and Older.*

Please share this bulletin with your staff and colleagues.